Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

EZH2 inhibitor

DRUG CLASS:

EZH2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1	valemetostat Sensitive: A1 - Approval valemetostat Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2	tazemetostat Sensitive: A2 - Guideline tazemetostat Sensitive : A2
ARID1A mutation	Endometrial Cancer	ARID1A mutation	Endometrial Cancer	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B	DZR123 Sensitive: B - Late Trials DZR123 Sensitive : B
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1	tazemetostat Sensitive: C1 - Off-label tazemetostat Sensitive : C1
SMARCB1 negative	Chordoma	SMARCB1 negative	Chordoma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
BAP1 mutation	Mesothelioma	BAP1 mutation	Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2	tazemetostat Sensitive: C2 – Inclusion Criteria tazemetostat Sensitive : C2
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2	DZR123 Sensitive: C2 – Inclusion Criteria DZR123 Sensitive : C2
EZH2 mutation	Follicular Lymphoma	EZH2 mutation	Follicular Lymphoma	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2	valemetostat Sensitive: C2 – Inclusion Criteria valemetostat Sensitive : C2
SMARCB1 negative	Spindle Cell Sarcoma	SMARCB1 negative	Spindle Cell Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
SMARCB1 deletion	Soft Tissue Sarcoma	SMARCB1 deletion	Soft Tissue Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3